Urinary tract infections caused by P-lactamase-producing bacteria were treated with 500 mg of amoxicillin three times daily plus either 250 or 125 mg of clavulanic acid three times daily. The overall cure rate was 63.6%, 77.7% with the high dose of clavulanic acid and 53.8% with the low dose. Gastrointestinal intolerance was common in the high-dose clavulanic acid regimen.
Formulations of amoxicillin with potassium clavulanate possess activity against many plasmid-mediated P-lactamase-producing bacteria (3, 4, 7-11, 13-15, 19) and have been used successfully in the therapy of urinary tract infections (1, 8) .
Two formulations were assessed in this trial, which included 22 adult in-patients (17 women and 5 men, ranging in age from 50 to 90 years) suffering from 24 episodes of urinary tract infection caused by amoxicillin-resistant organisms. Ten episodes (9 patients, group 1) were treated for 10 days with the 2:1 combination (500 mg of amoxicillin plus 250 mg of clavulanic acid administered three times daily), and fourteen episodes (13 patients, group 2) were treated with the 4:1 combination (500 mg of amoxicillin plus 125 mg of clavulanic acid administered three times daily). Tablets were taken with food. Exclusion criteria were allergy to P-lactams, renal impairment (creatinine clearance, <30 ml/ min), hepatic failure, bleeding disorders, bladder catheterization, recent administration of an effective antibiotic, and infection with an organism resistant to combinations of amoxicillin and clavulanic acid. Complete physical examinations were obtained before, during, and after treatment. Complete blood counts with differential leukocyte counts, platelets counts, hemoglobin levels, and concentrations of creatinine, urea, alkaline phosphatase, transaminases, and bilirubin in serum were also made at these times. "Clean-catch" urine was considered infected if yielding i105 organisms per ml on at least two separate occasions, together with significant pyuria (8) . Clinical pyelonephritis was confirmed by the presence of antibody-coated bacteria (18) . Antibiotic susceptibility was determined by an agar diffusion method (2), using filter-paper disks impregnated with amoxicillin alone (20 ,ug) and in combination with clavulanic acid (20 ,ug of amoxicillin and 10 ,ug of clavulanic acid), both kindly provided by Beecham Laboratories. Bacteria were considered susceptible if the diameter of the growth inhibition zone was >'19 mm and resistant if the zone was -14 mm. Minimal inhibitory concentrations (MICs) were determined by an agar dilution method. A multiinoculator (16) was used to deliver 4 x 103 colonyforming units per spot on the surfaces of Mueller-Hinton agar plates containing twofold serial dilutions of the combination over a suitable concentration range. The stock solution (300 ,ug/ml), prepared from pellets (provided by Beecham Laboratories) containing 2 mg of amoxicillin and 1 mg of clavulanic acid, was diluted in distilled water. The breakpoints were identical for amoxicillin alone and for the drug combination; i.e., bacteria were considered susceptible if <8 ,ug/ml of the combination (gramnegative rods) and s-3 ,ug/ml (gram-positive cocci) and resistant if :32 ,ug/ml (gram-negative rods). The MICs in Table 1 tions of patients' sera in 50% pooled serum and Mueller-Hinton medium (17) . The bacteriostatic value was the highest dilution preventing macroscopic growth (Table 1) . Two cases could not be assessed. In one case, patient 2 received only three doses and experienced severe vomiting; in the second case, patient 23 died suddenly. Septicemia was clinically suspected but not documented. Adequate longterm follow-up was seldom possible (mean 11 days; range, 1 day to 3 months). The overall cure rate was 63.6% (14 of 22 patients) and 77.7% (7 of 9 patients) with the 2:1 combination and 53.8% (7 of 13 patients) with the 4:1 combination. Superinfection occurred once. There were seven relapses. Three relapses might have been related to the underlying disease (patients 1, 18, and 20); four relapses may have been due to too short treatment (patients 1, 11, 13, and 14).
Upper digestive intolerance (nausea, vomiting, and gastric pain) was more common (5 of 10 patients) in the high-dose clavulanic group than in the low-dose group (2 of 14 patients). There was one case of diarrhea in each group. Two mild rashes and one generalized pruritus were also noted.
Zones of inhibition correlated well with MICs. The geometric means of the MICs were 11.7 ,ug/ ml in successful cases versus 4.4 ,ig/ml in failures. Success or failure was not tightly related, however, to the MIC. The bacteriostatic activity of the serum was low and never achieved the critical value of one-eighth (6) . This is probably of little importance in the treatment of urinary tract infections, but would be of more value in systemic infections, particularly those of the lung. Nevertheless, the geometric mean of the reciprocal titer in the high-dose clavulanic acid group was 5.66 in successful cases and 1.4 in failures.
The high incidence of adverse effects in the high-dose clavulanic acid was surprising, since it was contrary to the experience of most authors (1, 8, 13) . These patients received one of the earliest manufactured combinations, and this might be responsible for the poorer tolerance as observed by others (personal communication). The low-dose clavulanic acid combination was much better tolerated.
We concluded that combinations of 500 mg of amoxicillin plus 125 mg of clavulanic acid administered three times daily might be useful in the oral treatment of urinary tract infections caused by ampicillin-resistant strains, particularly in the elderly, and may allow one to avoid parenteral treatment.
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